VistaGen Therapeutics Inc (VTGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.01M
Last updated: Nov 17, 2026 at 11:04 AM ET
VistaGen Therapeutics Inc (VTGN) Financials: Revenue, Profit and Cash Flow
VistaGen Therapeutics reported revenue of $1.27M for the fiscal year ended Mar 31, 2026, up 161.1% from the year before. That year, net income was -$69.69M with a net margin of -5491.3%, operating cash flow was -$66.44M and free cash flow was -$66.59M. The quarter ended Sep 30, 2026 had revenue of $138.00K and net income of -$10.74M.
Revenue and Margins
Over the 9 years to Mar 2026, revenue grew from $1.25M, a compound annual rate of 0.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $1.27M | +161.1% | 100.0% | -5683.7% | -5491.3% |
| Mar 2025 | $486.00K | -54.3% | 100.0% | -11517.1% | -10579.8% |
| Mar 2024 | $1.06M | N/A | 100.0% | -3103.5% | -2759.6% |
| Mar 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Mar 2022 | $1.11M | +1.8% | 100.0% | -4308.7% | -4307.2% |
| Mar 2021 | $1.09M | N/A | 100.0% | -1646.1% | -1646.1% |
| Mar 2020 | $0 | N/A | N/A | N/A | N/A |
| Mar 2019 | $0 | N/A | N/A | N/A | N/A |
| Mar 2018 | $0 | -100.0% | N/A | N/A | N/A |
| Mar 2017 | $1.25M | N/A | 100.0% | -819.9% | -820.4% |
Income Statement
In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.27M | $486.00K | $1.06M | $0 | $1.11M | $1.09M | $0 | $0 | $0 | $1.25M |
| Gross profit | $1.27M | $486.00K | $1.06M | $0 | $1.11M | $1.09M | $0 | $0 | $0 | $1.25M |
| Research and development | $54.97M | $39.38M | $20.02M | $44.38M | $35.41M | $11.93M | $13.37M | $17.10M | $7.76M | $5.20M |
| Operating income | -$72.13M | -$55.97M | -$33.02M | -$59.27M | -$47.78M | -$17.93M | -$20.80M | -$24.56M | -$14.20M | -$10.25M |
| Net income | -$69.69M | -$51.42M | -$29.36M | -$59.25M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.35M | -$10.26M |
| EBITDA | -$71.39M | -$55.33M | -$32.14M | -$58.74M | -$47.07M | -$17.46M | -$20.68M | -$24.35M | -$13.97M | -$10.11M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $138.00K | $1.48M | $464.00K | $303.00K | $258.00K | $244.00K | -$15.00K | $234.00K | $183.00K | $84.00K | $198.00K | $411.00K |
| Gross profit | $138.00K | $1.48M | $464.00K | $303.00K | $258.00K | $244.00K | -$15.00K | $234.00K | $183.00K | $84.00K | $198.00K | $411.00K |
| Operating income | -$10.94M | -$13.35M | -$16.72M | -$19.55M | -$20.05M | -$15.80M | -$14.49M | -$15.12M | -$14.23M | -$12.13M | -$11.36M | -$7.88M |
| Net income | -$10.74M | -$13.03M | -$16.27M | -$18.90M | -$19.42M | -$15.10M | -$13.63M | -$14.09M | -$12.96M | -$10.73M | -$9.52M | -$6.35M |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded total debt of $192.00K by $30.60M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $48.56M | $84.34M | $123.65M | $21.09M | $74.64M | $108.28M | $5.77M | $14.01M | $11.28M | $3.71M |
| Current assets | $46.94M | $82.08M | $120.67M | $17.51M | $71.00M | $104.12M | $1.58M | $13.63M | $11.02M | $3.38M |
| Cash and equivalents | $30.79M | $67.13M | $119.17M | $16.64M | $68.14M | $103.11M | $1.36M | $13.10M | $10.38M | $2.92M |
| Total liabilities | $13.04M | $13.95M | $9.37M | $9.01M | $9.93M | $16.30M | $11.50M | $6.94M | $4.36M | $3.10M |
| Short-term debt | $96.00K | $561.00K | $550.00K | $105.00K | $0 | $367.80K | $56.50K | $57.30K | $56.50K | $57.20K |
| Long-term debt | $96.00K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | $9.00K | $12.00K |
| Shareholder equity | $35.52M | $70.39M | $114.29M | $12.08M | $64.72M | $91.98M | -$5.73M | $7.08M | $6.91M | $619.80K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $23.42M | $35.74M | $48.56M | $65.06M | $80.93M | $68.92M | $84.34M | $92.31M | $102.50M | $113.55M | $123.65M | $131.07M |
| Total liabilities | $8.43M | $11.26M | $13.04M | $14.14M | $14.59M | $12.16M | $13.95M | $11.19M | $9.52M | $8.74M | $9.37M | $7.78M |
| Cash and equivalents | $10.89M | $16.99M | $30.79M | $47.37M | $62.79M | $48.98M | $67.13M | $74.72M | $84.25M | $102.92M | $119.17M | $126.56M |
| Shareholder equity | $14.99M | $24.48M | $35.52M | $50.92M | $66.34M | $56.77M | $70.39M | $81.12M | $92.97M | $104.80M | $114.29M | $123.28M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$66.44M | -$42.10M | -$25.81M | -$49.72M | -$45.26M | -$12.07M | -$15.76M | -$14.53M | -$9.06M | -$7.26M |
| Capital expenditures | $151.00K | $191.00K | $61.00K | $528.00K | $0 | $275.40K | $0 | $174.00K | $1.60K | $239.10K |
| Free cash flow | -$66.59M | -$42.29M | -$25.87M | -$50.24M | -$45.26M | -$12.35M | -$15.76M | -$14.70M | -$9.06M | -$7.50M |
| Dividends paid | N/A | N/A | N/A | $866.96M | $945.10M | $1.39B | $1.26B | $1.14B | $1.03B | $1.26B |
| Investing cash flow | -$877.00K | -$13.15M | -$61.00K | -$740.00K | -$200.40K | -$275.40K | $0 | -$174.00K | -$1.60K | -$239.10K |
| Financing cash flow | $30.97M | $3.21M | $128.40M | -$1.04M | $10.48M | $114.10M | $4.01M | $17.42M | $16.52M | $9.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.16M | -$14.71M | -$16.20M | -$17.63M | -$13.76M | -$18.85M | -$10.06M | -$10.28M | -$10.89M | -$10.87M | -$6.99M | -$4.75M |
| Capital expenditures | N/A | $0 | $125.00K | $26.00K | $60.00K | $65.00K | $88.00K | $0 | $61.00K | $42.00K | $28.70K | $32.00K |
| Free cash flow | N/A | -$14.71M | -$16.32M | -$17.66M | -$13.82M | -$18.91M | -$10.15M | -$10.28M | -$10.95M | -$10.91M | -$7.01M | -$4.78M |
Frequently Asked Questions About VTGN
What is VistaGen Therapeutics' annual revenue?
VistaGen Therapeutics reported revenue of $1.27M for the fiscal year ended Mar 31, 2026.
How fast is VistaGen Therapeutics' revenue growing?
Revenue was up 161.1% for the fiscal year ended Mar 31, 2026 compared with the year before.
Is VistaGen Therapeutics profitable?
No. VistaGen Therapeutics reported net income of -$69.69M for the fiscal year ended Mar 31, 2026, with a net margin of -5491.3%.
How much free cash flow does VTGN generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$66.44M minus capital expenditures of $151.00K produced free cash flow of -$66.59M.
How much debt does VistaGen Therapeutics have?
The balance sheet dated Mar 31, 2026 reported long-term debt of $96.00K, short-term debt of $96.00K and cash and equivalents of $30.79M.
VTGN pages: Overview, Earnings, Forecast, Financials, Competitors